Search in:

Expert Opinion on Investigational Drugs Volume 18, 2009 - Issue 6

Submit an article Journal homepage

543

Views

CrossRef citations to date

Altmetric

Perspective

Current drugs and medical treatment algorithms in the management of acute decompensated heart failure

Filippos Triposkiadis University of Thessaly Medical School, Larissa University Hospital, Department of Cardiology, PO Box 1425, 411 10 Larissa, Greece +30 2410 682821; +30 2410 670112; [email protected]

, MD,

John T Parissis University of Athens, Attikon University Hospital, Heart Failure Clinic, Athens, Greece +30 210 6123720; +30 210 5832195; [email protected]

, MD,

Randall C Starling Heart Failure Center, Cleveland Clinic, Cleveland, USA

, MD,

John Skoularigis University of Thessaly Medical School, Larissa University Hospital, Department of Cardiology, PO Box 1425, 411 10 Larissa, Greece +30 2410 682821; +30 2410 670112; [email protected]

, MD &

George Louridas Cardiology Division of Aristotle University, Thessaloniki, Greece

, MD

Pages 695-707 | Published online: 09 May 2009

Cite this article
https://doi.org/10.1517/13543780902922660

Full Article
Figures & data
References
Citations
Metrics
Reprints & Permissions

Bibliography

Redfield MM. Heart failure: an epidemic of uncertain proportions. N Engl J Med 2002;347:1442-4
PubMed Web of Science ®Google Scholar
McCullough PA, Philbin EF, Spertus JA, et al. Confirmation of a heart failure epidemic: findings from the Resource Utilization Among Congestive Heart Failure (REACH) study. J Am Coll Cardiol 2002;39:60-9
PubMed Web of Science ®Google Scholar
Adams KF Jr, Fonarow GC, Emerman CL, et al. ADHERE Scientific Advisory Committee and Investigators. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 2005;149:209-16
PubMed Web of Science ®Google Scholar
Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur J Heart Fail 2008;10:933-89
PubMed Web of Science ®Google Scholar
Fonarow GC, Adams Jr KF, Abraham WT, et al. Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA 2005;293:572-80
PubMed Web of Science ®Google Scholar
Gheorghiade M, Zannad F, Sopko G, et al. Acute heart failure syndromes: current state and framework for future research. Circulation 2005;112:3958-68
PubMed Web of Science ®Google Scholar
Nieminen MS, Brutsaert D, Dickstein K, et al. EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. Eur Heart J 2006;27:2725-36
PubMed Web of Science ®Google Scholar
Cotter G, Metra M, Milo-Cotter O, et al. Fluid overload in acute heart failure: re-distribution and other mechanisms beyond fluid accumulation. Eur J Heart Fail 2008;10(2):165-9
PubMed Web of Science ®Google Scholar
Tavazzi L, Maggioni AP, Lucci D, et al. Nationwide survey on acute heart failure in cardiology ward services in Italy. Eur Heart J 2006;27:1207-15
PubMed Web of Science ®Google Scholar
Fonarow G. Acute decompensated heart failure: challenges and opportunities. Rev Cardiovasc Med 2007;8 (Suppl 5):S3-S12
PubMed Web of Science ®Google Scholar
Reynolds HR, Hochman JS. Cardiogenic shock: current concepts and improving outcomes. Circulation 2008;117:686-97
PubMed Web of Science ®Google Scholar
Felker GM, Cotter G. Unraveling the pathophysiology of acute heart failure: an inflammatory proposal. Am Heart J 2006;151:765-7
PubMed Web of Science ®Google Scholar
Karayannis G, Kitsios G, Kotidis H, Triposkiadis F. Left atrial remodelling contributes to the progression of asymptomatic left ventricular systolic dysfunction to chronic symptomatic heart failure. Heart Fail Rev 2008;13:91-8
PubMed Web of Science ®Google Scholar
Triposkiadis F, Giamouzis G, Kelepeshis G, et al. Acute hemodynamic effects of moderate doses of nebivolol versus metoprolol in patients with systolic heart failure. Int J Clin Pharmacol Ther 2007;45:71-7
PubMed Web of Science ®Google Scholar
Mann DL, Bristow MR. Mechanisms and models in heart failure: the biomechanical model and beyond. Circulation 2005;111:2837-49. Erratum in: Circulation 2005;112(4):e75
PubMed Web of Science ®Google Scholar
Feldman DS, Elton TS, Sun B, et al. Mechanisms of disease: detrimental adrenergic signaling in acute decompensated heart failure. Nat Clin Pract Cardiovasc Med 2008;5:208-18
PubMedGoogle Scholar
Colombo PC, Onat D, Sabbah HN. Acute heart failure as ‘acute endothelitis’--Interaction of fluid overload and endothelial dysfunction. Eur J Heart Fail 2008;10:170-5
PubMed Web of Science ®Google Scholar
Rastogi A, Fonarow GC. The cardiorenal connection in heart failure. Curr Cardiol Rep 2008;10:190-7
PubMedGoogle Scholar
Bongartz LG, Cramer MJ, Doevendans PA, et al. The severe cardiorenal syndrome: ‘Guyton revisited’. Eur Heart J 2005;26:11–17
Google Scholar
Geisberg C, Butler J. Addressing the challenges of cardiorenal syndrome. Cleve Clin J Med 2006;73:485-91
PubMed Web of Science ®Google Scholar
Mullens W, Abrahams Z, Skouri HN, et al. Elevated intra-abdominal pressure in acute decompensated heart failure: a potential contributor to worsening renal function? J Am Coll Cardiol 2008;51:300-6
PubMed Web of Science ®Google Scholar
Mullens W, Abrahams Z, Francis G, et al. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol 2009;53:589-96
PubMed Web of Science ®Google Scholar
Fonarow GC. Epidemiology and risk stratification in acute heart failure. Am Heart J 2008;155:200-7
PubMed Web of Science ®Google Scholar
Nicol ED, Fittall B, Roughton M, et al. NHS heart failure survey: a survey of acute heart failure admissions in England, Wales and Northern Ireland. Heart 2008;94:172-7
PubMed Web of Science ®Google Scholar
Siirilä-Waris K, Lassus J, Melin J, et al. Characteristics, outcomes, and predictors of 1-year mortality in patients hospitalized for acute heart failure. Eur Heart J 2006;27:3011-7
PubMed Web of Science ®Google Scholar
Blackledge HM, Tomlinson J, Squire IB. Prognosis for patients newly admitted to hospital with heart failure: survival trends in 12 220 index admissions in Leicestershire 1993-2001. Heart 2003;89:615-20
PubMed Web of Science ®Google Scholar
Zannad F, Mebazaa A, Juillière Y, et al. Clinical profile, contemporary management and one-year mortality in patients with severe acute heart failure syndromes: The EFICA study. Eur J Heart Fail 2006;8:697-705
PubMed Web of Science ®Google Scholar
Krumholz HM, Wang Y, Parent EM, et al. Quality of care for elderly patients hospitalized with heart failure. Arch Intern Med 1997;157:2242-7
PubMed Web of Science ®Google Scholar
Fonarow GC, Abraham WT, Albert NM, et al. Factors identified as precipitating hospital admissions for heart failure and clinical outcomes: findings from OPTIMIZE-HF. Arch Intern Med 2008;168:847-54
PubMed Web of Science ®Google Scholar
Westert GP, Lagoe RJ, Keskimaki I, et al. An international study of hospital readmissions and related utilization in Europe and the USA. Health Policy 2002;61:269-78
PubMed Web of Science ®Google Scholar
Levy D, Kenchaiah S, Larson MG, et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med 2002;347:1397-402
PubMed Web of Science ®Google Scholar
Peter JV, Moran JL, Phillips-hughes J, et al. Effect of non-invasive positive pressure ventilation (NIPPV) on mortality in patients with acute cardiogenic pulmonary edema: a meta-analysis. Lancet 2006;367:1155–1163
Google Scholar
Gray A, Goodacre S, Newby DE, et al.; 3CPO Trialists. Non-invasive ventilation in acute cardiogenic pulmonary oedema. N Engl J Med 2008;359:142-51
PubMed Web of Science ®Google Scholar
Peacock WF, Hollander JE, Diercks DB, et al. Morphine and outcomes in acute decompensated heart failure: an ADHERE analysis. Emerg Med J 2008;25:205-9
PubMed Web of Science ®Google Scholar
Cotter G, Metzkor E, Kaluski E, et al. Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary edema. Lancet 1998;351:389-93
PubMed Web of Science ®Google Scholar
Elkayam U, Akhter MW, Singh H, et al. Comparison of effects on left ventricular filling pressure of intravenous nesiritide and high-dose nitroglycerin in patients with decompensated heart failure. Am J Cardiol 2004;93:237-40
PubMed Web of Science ®Google Scholar
Goldenberg IF, Lewis WR, Dias VC, et al. Intravenous diltiazem for the treatment of patients with atrial fibrillation or flutter and moderate to severe congestive heart failure. Am J Cardiol 1994;74:884-9
PubMed Web of Science ®Google Scholar
Domanski M, Norman J, Pitt B, et al. Diuretic use, progressive heart failure, and death in patients in the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 2003;42:705-8
PubMed Web of Science ®Google Scholar
Metra M, Nodari S, Parinello G, et al. Worsening renal function in patients hospitalized for acute heart failure: clinical implications and prognostic significance. Eur J Heart Fail 2008;10:188-95
PubMed Web of Science ®Google Scholar
Damman K, Navis G, Voors A, et al. Worsening renal function and prognosis in heart failure: systematic review and meta-analysis. J Card Fail 2007;13:599-608
PubMed Web of Science ®Google Scholar
Patel J, Smith M, Heywood JT. Optimal use of diuretics in patients with heart failure. Curr Treat Options Cardiovasc Med 2007;9:332-42
PubMedGoogle Scholar
Yancy CW. B-type natriuretic peptides in management of acute decompensated heart failure. Heart Fail Clin 2006;2:353-64
PubMedGoogle Scholar
Publication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute CHF). Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA 2002;287:1531-40
PubMed Web of Science ®Google Scholar
Yancy CW. Benefit-risk assessment of nesiritide in the treatment of acute decompensated heart failure. Drug Saf 2007;30:765-81
PubMed Web of Science ®Google Scholar
Sackner-bernstein JD, Kowalski M, Fox M, Aaronson K. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA 2005;293:1900-5
PubMed Web of Science ®Google Scholar
Witteles RM, Kao D, Christopherson D, et al. Impact of nesiritide on renal function in patients with acute decompensated heart failure and pre-existing renal dysfunction: a randomized, double-blind, placebo controlled clinical trial. J Am Coll Cardiol 2007;50:1835-40
PubMed Web of Science ®Google Scholar
Mentzer RM, Oz MC, Sladen RN, et al. Effects of perioperative nesiritide in patients with left ventricular dysfunction undergoing cardiac surgery. J Am Coll Cardiol 2007;49:716-26
PubMed Web of Science ®Google Scholar
Yancy C. Follow-up Serial Infusions of Nesiritide in Advanced Heart Failure (FUSION II). Paper presented at: American College of Cardiology Annual Scientific Session; March 24 – 27, 2007; New Orleans, LA
Google Scholar
Hernandez AF, O'Connor CM, Starling RC, et al. Rationale and design of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF). Am Heart J 2009;157:271-7
PubMed Web of Science ®Google Scholar
Costanzo MR, Guglin ME, Saltzberg MT, et al. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 2007;49:675-83
PubMed Web of Science ®Google Scholar
Elkayam U, Ng TM, Hatamizadeh P, et al. Renal vasodilatory action of dopamine in patients with heart failure: magnitude of effect and site of action. Circulation 2008;117:200-5
PubMed Web of Science ®Google Scholar
Petersen JW, Felker GM. Inotropes in the management of acute heart failure. Crit Care Med 2008;36(1 Suppl):S106-11
PubMedGoogle Scholar
Chatterjee K, Bendersky R, Parmley WW. Dobutamine in heart failure. Eur Heart J 1982;3(Suppl D):107-14
PubMedGoogle Scholar
Hatzizacharias A, Makris T, Krespi P, et al. Intermittent milrinone effect on long-term hemodynamic profile in patients with severe congestive heart failure. Am Heart J 1999;138(2 Pt 1):241-6
PubMed Web of Science ®Google Scholar
Metra M, Nodari S, D'Aloia A, et al. Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol. J Am Coll Cardiol 2002;40:1248-58
PubMed Web of Science ®Google Scholar
Triposkiadis F, Dalampiras P, Kelepeshis G, et al. Hemodynamic effects of dobutamine in patients with an exacerbation of chronic systolic heart failure treated with low doses of carvedilol. Int J Clin Pharmacol Ther 2008;46:136-9
PubMed Web of Science ®Google Scholar
Antila S, Sundberg S, Lehtonen LA. Clinical pharmacology of levosimendan. Clin Pharmacokinet 2007;46:535-52
PubMed Web of Science ®Google Scholar
Parissis J, Farmakis D, Nieminen M. Classical inotropes and new cardiac enhancers. Heart Fail Rev 2007;12:149-56
PubMed Web of Science ®Google Scholar
Follath F, Cleland JG, Just H, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomized double-blind trial. Lancet 2002;360:196-202
PubMed Web of Science ®Google Scholar
Mebazaa A, Nieminen MS, Packer M, et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA 2007;297:1883-91
PubMed Web of Science ®Google Scholar
Mebazaa A, Nieminen M, Filippatos G, et al. Levosimendan vs. dobutamine: outcomes for acute heart failure patients on beta-blockers in SURVIVE. Eur J Heart Fail 2009;11(3):304-11
PubMed Web of Science ®Google Scholar
Parissis J, Andreadou I, Bistola V, et al. Novel biologic mechanisms of levosimendan and its effect on the failing heart. Expert Opin Investig Drugs 2008;17(8):1143-50
PubMed Web of Science ®Google Scholar
Parissis J, Rafouli-stergiou P, Paraskevaidis I, Mebazaa A. Levosimendan: from basic science to clinical practice. Heart Fail Rev 2008 [Epub ahead of print]
Google Scholar
Bankir L. Antidiuretic action of vasopressin: quantitative aspects and interaction between V1a and V2-receptor-mediated effects. Cardiovasc Res 2001;51:372-90
PubMed Web of Science ®Google Scholar
Filippatos G, Parissis JT. Vasopressin antagonists for the treatment of acute decompensated heart failure: when, for whom, for how long, and on what standard therapy? J Card Fail 2008;14:648-50
PubMed Web of Science ®Google Scholar
Gheorghiade M, Gattis WA, O'Connor CM, et al.; for the Acute and Chronic Therapeutic Impact of or Vasopressin Antagonist in Congestive Heart Failure (ACTIV in CHF) Investigators. Effects of Tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA 2004;291:1963-71
PubMed Web of Science ®Google Scholar
Gheorghiade M, Konstam MA, Burnett JC, et al.; for the efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) Investigators. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA 2007;297:1332-43
PubMed Web of Science ®Google Scholar
Konstam MA, Gheorghiade M, Burnett JC, et al. Efficacy of vasopressin antagonist in heart failure outcome study with Tolvaptan (EVEREST) Investigators. Effects of oral Tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 2007;297:1319-31
PubMed Web of Science ®Google Scholar
Abraham WT, Shamshirsaz AA, Mefann K, et al. Aquaretic effect of Lixivaptan, an oral, non-peptide, selective V2-receptor vasopressin antagonist, in New York Heart Association functional class II and III chronic heart failure patients. J Am Coll Cardiol 2006;47:1615-21
PubMed Web of Science ®Google Scholar
Vallon V, Miracle C, Thomson S. Adenosine and kidney function: potential implications in patients with heart failure. Eur J Heart Fail 2008;10:176-87
PubMed Web of Science ®Google Scholar
Kim SM, Mizel D, Huang YG, et al. Adenosine as a mediator of macula densa-dependent inhibition of renin secretion. Am J Physiol Renal Physiol 2006;290:F1016-23
PubMed Web of Science ®Google Scholar
Quintana M, Kahan T, Hjemdahl P. Pharmacological prevention of reperfusion injury in acute myocardial infarction. A potential role for adenosine as a therapeutic agent. Am J Cardiovasc Drugs 2004;4:159-67
PubMedGoogle Scholar
Givertz MM, Massie BM, Fields TK, Pearson LL, Dittrich HC; CKI-201 and CKI-202 Investigators. The effects of KW-3902, an adenosine A1-receptor antagonist on diuresis and renal function in patients with acute decompensated heart failure and renal impairment or diuretic resistance. J Am Coll Cardiol 2007;50:1551-60
PubMed Web of Science ®Google Scholar
Bragadeesh TK, Mathur G, Clark AL, Cleland JG. Novel cardiac myosin activators for acute heart failure. Expert Opin Investig Drugs 2007;16:1541-8
PubMed Web of Science ®Google Scholar
Teerlink JR. The selective cardiac myosin activator CK-1827452, a calcium-independent inotrope, increases LV systolic function by increasing ejection time: results of a first-in-human study of a unique and novel mechanism. Presented at the 10th Annual Scientific Meeting of the Heart Failure Society of America; September 10-13, 2006; Seattle, Washington
Google Scholar
Muller OJ, Lange M, Rattunde H, et al. Transgenic rat hearts over expressing SERCA2a show improved contractility under baseline conditions and pressure overload. Cardiovasc Res 2003;59:380-9
PubMed Web of Science ®Google Scholar
Gheorghiade M, Blair JE, Filippatos GS, et al. Hemodynamic, echocardiographic, and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure. J Am Coll Cardiol 2008;51:2276-85
PubMed Web of Science ®Google Scholar
De Luca L, Mebazaa A, Filippatos G, et al. Overview of emerging pharmacologic agents for acute heart failure syndromes. Eur J Heart Fail 2008;10:201-13
PubMed Web of Science ®Google Scholar
Mitrovic V, Seferovic PM, Simeunovic D, et al. Hemodynamic and clinical effects of ularitide in decompensated heart failure. Eur Heart J 2006;27:2823-32
PubMed Web of Science ®Google Scholar
Dschietzig T, Richter C, Bartsch C, et al. The pregnancy hormone relaxin is a player in human heart failure. Faseb J 2001;15:2187-95
PubMed Web of Science ®Google Scholar
Kupari M, Mikkola TS, Turto H, Lommi J. Is the pregnancy hormone relaxin an important player in human heart failure? Eur J Heart Fail 2005;7:195-8
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Current drugs and medical treatment algorithms in the management of acute decompensated heart failure

Bibliography

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Current drugs and medical treatment algorithms in the management of acute decompensated heart failure

Bibliography

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date